TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)

Summary

This study is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of single-dose TD-3504 and single dose 15N2-tofacitinib in healthy subjects and subjects with UC. The relative bioavailability of tofacitinib released from TD-3504 compared to co-administered oral heavy-labeled tofacitinib (15N2-tofacitinib) will also be evaluated.

Timeline

Start

2017-05-04

Primary completion

2017-11-08

Completion

2017-11-08

Drugs

Indications